A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria: * Histologic documentation of incurable, locally advanced, or metastatic solid malignancy that has failed to respond to at least one prior regimen or for which there is no standard therapy * Disease that is measurable or evaluable by Response Evaluation Criteria In Solid Tumors (RECIST) * Life expectancy ≥12 weeks Exclusion Criteria: * Less than 4 weeks since the last anti-tumor therapy * Patients receiving erythropoietin products * Active infection requiring antibiotics * Active autoimmune disease that is not controlled by nonsteroidal anti-inflammatory drugs * Symptomatic hypercalcemia requiring continued use of bisphosphonate therapy * Clinically important history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis * Known human immunodeficiency virus infection * Primary central nervous system (CNS) malignancy, or untreated/active CNS metastases